Gilead Sciences Inc
NASDAQ: GILD
$90.19
+$0.43 (+0.5%)
Closing Price on November 22, 2024
GILD Articles
The top analyst upgrades, downgrades and initiations seen on Wednesday morning include Abercrombie & Fitch, Alibaba, Baidu, First Data, Marvell Technology and Under Armour.
Published:
Last Updated:
August 29, 2016: Here are four stocks trading with relatively heavy volume among 21 equities making new 52-week lows in Monday’s session. NYSE advancers led decliners by about 7 to 3 and Nasdaq...
Published:
Last Updated:
The August 15 short interest data have been compared with the previous report, and short interest moves were mixed across these selected biotech stocks.
Published:
Last Updated:
Medivation has been among the top future biotech mergers for quite some time. The problem is that we still have no idea which company will buy Medivation, nor do we know what price.
Published:
Last Updated:
Investors are now focusing on fundamentals and near-term catalysts that could provide a tailwind for some of the biotech leaders.
Published:
Last Updated:
The short interest data are out for the July 29 settlement date and short interest decreased across these selected biotech stocks.
Published:
Last Updated:
Finally, concerns about biotech seem to be waning. An RBC research report notes that at the recent political conventions there was little to no mention of drug pricing.
Published:
Last Updated:
Gilead Sciences reported its earnings on Monday of last week, and since that time there has been much analyst activity around the stock.
Published:
Last Updated:
The recent performance from Gilead Sciences has analysts and investors concerned about the future. Argus believes that the headwinds are blowing harder than the tailwinds for the company.
Published:
Last Updated:
The top analyst upgrades, downgrades and initiations seen on Friday morning include Alphabet, Amazon, Dow Chemical, Ford, Gilead, Harley-Davidson and Western Digital.
Published:
Last Updated:
The short interest data are out for the July 15 settlement date. Short interest increased across many of these selected biotech stocks.
Published:
Last Updated:
Overall, the Gilead Sciences report was not good and investors took to dumping the stock. On the other hand, this could provide a buying opportunity since shares are just off of their 52-week lows.
Published:
Last Updated:
The top analyst upgrades, downgrades and initiations seen on Tuesday morning include Gilead Sciences, Sprint, Starbucks, Southwest Airlines, Texas Instruments, Walt Disney and Nordstrom.
Published:
Last Updated:
Although Gilead Sciences is one of the world’s leading biotech companies, an earnings beat in its latest report was not enough to satisfy investors.
Published:
Last Updated:
Gilead Sciences is scheduled to release its second-quarter financial results after the markets close on Monday.
Published:
Last Updated: